Valuation: Physiomics Plc

Market Cap 2.13M 2.9M 2.49M 2.33M 4M 278M 4.05M 27.49M 10.72M 140M 10.9M 10.66M 462M P/E 2026 *
-4.7x
P/E 2027 * -
Enterprise Value 1.86M 2.54M 2.18M 2.04M 3.5M 243M 3.54M 24.06M 9.38M 122M 9.54M 9.33M 404M EV / Sales 2026 *
1.86x
EV / Sales 2027 * -
Free-Float
76.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Physiomics Plc

1 week+4.44%
Current month-2.08%
1 month-6.00%
3 months-27.69%
6 months-6.00%
Current year+64.91%
1 week 0.43
Extreme 0.43
0.5
1 month 0.41
Extreme 0.41
0.55
Current year 0.25
Extreme 0.2525
0.8
1 year 0.25
Extreme 0.2525
0.8
3 years 0.25
Extreme 0.2525
3.19
5 years 0.25
Extreme 0.2525
7.28
10 years 0.25
Extreme 0.2525
32
Manager TitleAgeSince
Director of Finance/CFO 52 -
Chief Operating Officer - 01/07/2026
Corporate Officer/Principal - 31/08/2021
Director TitleAgeSince
Director/Board Member - 29/04/2026
Chairman 53 29/04/2026
Director/Board Member - 29/04/2026
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Buy

Director

3,000,000 0.6619%
7/10/26 A Buy

Director

1,111,111 0.2452%
11/8/24 A Buy

Chief Executive Officer

459,090 0.2259%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.44%+10.59%-51.79% 2.91M
-0.59%+2.71%-22.14%+13.65% 127B
-0.25%+1.45%-41.45%-16.81% 45.92B
-0.86%-0.76%-0.44%+7.63% 41.35B
+0.14%+6.73%-21.36%+0.69% 22.61B
+0.62%+2.06%-37.93%-34.69% 18.43B
-0.53%-3.88%+1.16%+58.50% 16.22B
-0.26%+5.48%-2.02%+10.22% 16.31B
-0.89%+5.15%-20.93%-30.68% 10.67B
-2.13%-13.15%+17.84%+34.31% 3.55B
Average -0.48%+0.78%-11.67%-0.90% 30.24B
Weighted average by Cap. -0.47%+1.23%-20.16%+5.19%

Financials

2026 *2027 *
Net sales 1M 1.36M 1.17M 1.09M 1.88M 130M 1.9M 12.91M 5.03M 65.51M 5.12M 5.01M 217M -
Net income -314K -428K -367K -343K -589K -40.95M -597K -4.05M -1.58M -20.57M -1.61M -1.57M -68.04M -
Net Debt -266K -363K -311K -291K -499K -34.69M -506K -3.43M -1.34M -17.43M -1.36M -1.33M -57.64M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
10
Date Price Change Volume
21/08/26 GBX 0.4700 0.00% 1,888,647
20/08/26 GBX 0.4700 0.00% 72,495
19/08/26 GBX 0.4700 0.00% 502,512
18/08/26 GBX 0.4700 +4.44% 11,256,678
17/08/26 GBX 0.4500 0.00% 2,483,303

Annual profits - Rate of surprise